- Home
- NCNA vs ICU Comparison
NCNA vs ICU Comparison
Compare NCNA & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCNA | ICU |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 9.1M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | NCNA | ICU |
|---|---|---|
| Price | $1.93 | $2.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.1K | ★ 44.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,043.70 |
| Revenue Next Year | N/A | $54.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.22 |
| 52 Week High | $10.00 | $2.98 |
Technical Indicators
Market Signals| Indicator | NCNA | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 38.11 | 66.79 |
| Support Level | $0.04 | $2.26 |
| Resistance Level | $2.27 | $2.98 |
| Average True Range (ATR) | 0.16 | 0.19 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 25.68 | 88.46 |
Price Performance
Historical ComparisonAbout NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.